We have located links that may give you full text access.
IMP3 is upregulated in primary ovarian mucinous carcinoma and promotes tumor progression.
OBJECTIVE: Primary ovarian mucinous tumors progress from benign adenoma to borderline tumors to invasive mucinous carcinoma. A proper differential diagnosis is crucial to discriminate malignancies at the early stages of disease. However, few biomarkers are clinically available. We designed this study to analyze the clinical application of the oncogene IMP3 in monitoring early malignancies in ovarian primary mucinous tumors.
METHODS: We collected 250 samples of ovarian primary mucinous tumors along with the corresponding clinicopathological information between 2009 and 2015 at the Gynecology and Obstetrics Hospital of Fudan University and performed immunochemical assays. Statistical analysis of the correlation between expression of IMP3 and clinic-pathological parameters as well as the survivals of these patients was carried out. Finally, wound-healing and transwell assays were performed in SKOV3 and CAOV3 cells.
RESULTS: The expression rate and intensity of IMP3 were much higher in invasive carcinoma than those in benign adenoma and classic borderline adenoma (P<0.05). The expression rate and intensity of IMP3 were also higher in cases with mucinous intraepithelial carcinoma than those in cases with classic borderline tumors (P<0.05). Among the malignant cases, the expression rate and intensity of IMP3 increased with advancing FIGO staging (P<0.05). The expression rate and intensity of IMP3 were much higher in cases with involved fallopian tubes, uterine and omentum than those in cases without the involvement of these tissues (P<0.05). The expression rate and intensity of IMP3 were much higher in cases with lymph node metastasis than those in cases without lymph node metastasis (P<0.05). Elevated expression of IMP3 significantly deteriorated the disease-free survival (DFS) and overall survival (OS) of mucinous carcinoma (P<0.05). IMP3 was an independent risk factor of DFS but not OS. Further in vitro experiments indicated that IMP3 promoted the proliferation, motility and invasive potential of ovarian tumor cells.
CONCLUSIONS: IMP3 is highly expressed in ovarian mucinous tumors and is positively correlated with malignancy. IMP3 could be used in the differential diagnosis of ovarian mucinous tumors and might be applicable in monitoring tumor initiation and progression.
METHODS: We collected 250 samples of ovarian primary mucinous tumors along with the corresponding clinicopathological information between 2009 and 2015 at the Gynecology and Obstetrics Hospital of Fudan University and performed immunochemical assays. Statistical analysis of the correlation between expression of IMP3 and clinic-pathological parameters as well as the survivals of these patients was carried out. Finally, wound-healing and transwell assays were performed in SKOV3 and CAOV3 cells.
RESULTS: The expression rate and intensity of IMP3 were much higher in invasive carcinoma than those in benign adenoma and classic borderline adenoma (P<0.05). The expression rate and intensity of IMP3 were also higher in cases with mucinous intraepithelial carcinoma than those in cases with classic borderline tumors (P<0.05). Among the malignant cases, the expression rate and intensity of IMP3 increased with advancing FIGO staging (P<0.05). The expression rate and intensity of IMP3 were much higher in cases with involved fallopian tubes, uterine and omentum than those in cases without the involvement of these tissues (P<0.05). The expression rate and intensity of IMP3 were much higher in cases with lymph node metastasis than those in cases without lymph node metastasis (P<0.05). Elevated expression of IMP3 significantly deteriorated the disease-free survival (DFS) and overall survival (OS) of mucinous carcinoma (P<0.05). IMP3 was an independent risk factor of DFS but not OS. Further in vitro experiments indicated that IMP3 promoted the proliferation, motility and invasive potential of ovarian tumor cells.
CONCLUSIONS: IMP3 is highly expressed in ovarian mucinous tumors and is positively correlated with malignancy. IMP3 could be used in the differential diagnosis of ovarian mucinous tumors and might be applicable in monitoring tumor initiation and progression.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app